Contrive Datum Insights has published "Home Infusion Therapy Services Market Size, Share & Industry Analysis, By Type (Intravenous set, Needleless catheter, Infusion pump), Application (Chemotherapy, Diabetes, Hydration therapy, Inotropic therapy, Pain management, HIV therapies, Post-transplant therapies, Total parenteral nutrition, Hemophilia therapies, Others), Component (Devices & Equipment, Consumables, Services), End user (Home Care Settings, Specialty Pharmacies, Hospital-Based Home Infusion Providers, Skilled Nursing Facilities), Route of administration (Central Venous Access, Peripheral Venous Access), and Regional Forecast, 2026-2034". The study sizes the global home infusion therapy services market at USD 42 billion in 2025 and projects growth from USD 45.6 billion in 2026 to USD 91.1 billion by 2034, a compound annual growth rate of 9.04% across the forecast period.
Home infusion therapy services cover intravenous and subcutaneous drug and nutrient administration delivered in a patient's home rather than a hospital or outpatient clinic. The category spans the devices used to deliver therapy, such as infusion pumps, administration sets and needleless connectors, the consumable supplies that support each course of treatment, and the clinical and logistics services, including nursing visits, pharmacy compounding and delivery coordination, that keep a therapy running safely outside a facility. Buyers include home health agencies, specialty pharmacies, hospital-based home infusion programs and the payers that reimburse this care.
Shift of complex infusion therapies from hospital to home settings
Shift of complex infusion therapies from hospital to home settings is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 9.04% a year, the type lines exposed to it move fastest: Needleless catheter compounds at 9.61%, taking its share of revenue from 20.95% to 21.95% and its value from USD 8.8 billion to USD 20 billion.
On the upside, the study's bull case assumes the bull case assumes faster payer adoption of home-based infusion reimbursement across major markets and quicker scaling of specialty pharmacy networks, pulling forward volume that would otherwise arrive later in the forecast, which would take 2034 revenue to USD 97.9 billion rather than the USD 91.1 billion base case.
However, the bear case assumes reimbursement policy tightens in key markets and the home infusion nursing shortage persists longer than expected, slowing the pace at which complex therapies shift out of hospital settings, which would hold 2034 revenue to USD 80 billion. Intravenous set, which carries 35% of 2025 revenue, already grows at only 7.98% against the market's 9.04%, so the largest part of the base is also its slowest.
Key Players Compete on Infusion pump Volume and Needleless catheter Growth
Competition in the global home infusion therapy services market runs along the type axis rather than the regional one. Infusion pump holds 44.05% of 2025 revenue at USD 18.5 billion and remains the largest line through 2034 at 45.99%, making it the position hardest for a challenger to take. Needleless catheter, growing at 9.61%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 42 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Infusion pump | 44.05% · USD 18.5 billion | — |
| Application | Chemotherapy | 22.14% · USD 9.3 billion | Diabetes 10.12% |
| Component | Devices & Equipment | 40% · USD 16.8 billion | Services 9.89% |
| End user | Home Care Settings | 55% · USD 23.1 billion | — |
| Route of administration | Central Venous Access | 61.9% · USD 26 billion | — |
- Based on regional analysis, North America led the global home infusion therapy services market in 2025 with 43.3% of global revenue at USD 18.2 billion, reaching USD 36.4 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 21% in 2025 to 26% in 2034, with revenue growing from USD 8.8 billion to USD 23.7 billion.
- Latin America remains the smallest region throughout, at 4.3% of 2025 revenue and 5% by 2034.
- Needleless catheter is projected to grow at 9.61% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 14.2 billion in 2025, 33.8% of global revenue.
The report segments the market across five axes; by type, and by application, component, end user and route of administration; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 80 billion and USD 97.9 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.